Revance therapeutics, inc. (RVNC)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Revenue

193

413

812

3,128

3,814

3,729

3,278

991

380

262

300

300

300

300

300

300

300

300

300

300

300

383

617

700

700

617

0

0

0

Gross profit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Operating expenses:
Research and development

118,660

102,861

100,910

96,911

94,256

92,500

87,960

87,755

83,191

80,361

71,888

60,541

57,426

50,381

52,808

55,528

50,639

47,529

41,702

37,286

35,093

33,390

30,499

28,183

27,855

27,831

0

0

0

Selling, general and administrative

70,325

62,011

56,603

54,019

53,157

53,863

52,392

47,385

43,260

37,398

32,611

30,965

29,374

29,075

28,880

27,205

26,547

25,088

22,976

22,449

20,946

19,043

17,253

14,095

12,879

11,011

0

0

0

Loss on impairment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

Total operating expenses

188,985

164,872

157,513

150,930

147,413

146,363

143,279

138,067

129,378

120,686

111,609

98,616

95,859

88,515

83,637

84,682

77,186

72,617

64,678

59,735

56,039

52,433

47,752

42,278

40,734

38,842

0

0

0

Loss from operations

-188,792

-164,459

-156,701

-147,802

-143,599

-142,634

-140,001

-137,076

-128,998

-120,424

-111,309

-98,316

-95,559

-88,215

-83,337

-84,382

-76,886

-72,317

-64,378

-59,435

-55,739

-52,050

-47,135

-41,578

-40,034

-38,225

0

0

0

Interest income

5,453

5,532

5,419

5,086

4,571

4,023

3,510

2,855

2,121

1,410

1,229

1,194

1,171

1,170

1,027

789

514

231

171

117

69

44

19

0

0

-

-

0

-

Interest expense

2,148

0

0

0

0

44

63

167

308

457

663

815

960

1,082

1,213

1,347

1,340

1,190

1,170

1,008

996

10,672

12,035

12,158

12,381

15,164

0

0

0

Change in fair value of derivative liabilities associated with convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,032

0

0

0

-

-

-

-

Changes in fair value of derivative liability

-197

-199

-130

-107

-198

-140

-529

-528

-565

-591

-225

-348

-654

-608

-527

-347

155

127

165

219

54

-320

0

0

0

-

-

-

-

Change in fair value of common stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,151

0

0

0

-

-

-

-

Change in fair value of convertible preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-210

0

0

0

-

-

-

-

Loss on settlement of preferred stock warrant

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,356

0

0

0

-

-

-

-

Other expense, net

-274

-303

-308

-322

-609

-773

-774

-758

-718

-525

-515

-525

-536

-535

-512

-472

-405

-327

-382

-289

-281

-234

-437

-470

-406

-404

0

0

0

Loss before income taxes

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Income tax provision

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net Income (Loss) Attributable to Parent

-185,996

-159,400

-154,721

-146,155

-142,835

-142,568

-137,857

-135,674

-128,468

-120,587

-111,513

-98,840

-96,568

-89,300

-84,562

-85,759

-77,962

-73,476

-65,594

-60,396

-56,893

-62,917

-58,784

-53,690

-52,217

-52,448

0

0

0

Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax

454

11

176

340

346

-8

-92

-110

-179

45

-58

-262

-283

-5

6

160

186

-40

10

-12

0

-

0

0

-

-

-

-

-

Comprehensive loss

-185,604

-159,418

-154,544

-145,805

-142,489

-142,576

-137,949

-135,784

-128,647

-120,542

-111,541

-99,072

-96,821

-89,275

-84,556

-85,599

-77,776

-73,516

-65,349

-59,498

0

-

0

0

-

-

-

-

-

Net loss attributable to common stockholders:
Basic and diluted net loss

-186,058

-159,429

-154,720

-146,145

-142,835

-142,568

-137,857

-135,674

-128,468

-120,587

-111,483

-98,810

-96,538

-89,270

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-25,120

-23,936

-26,384

258

0

0

0

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-32,428

-31,244

-33,692

1,083

0

0

0

Net loss per share attributable to common stockholders (Note 12):
Basic and diluted net loss (in dollar per share)

-1.15

-1.00

-0.96

-0.86

-0.85

-1.12

-0.91

-0.94

-0.97

-1.16

-1.01

-0.90

-0.94

-0.95

-0.64

-0.88

-0.71

-

-

-

-

-

-

-

-

-

-

-

-

Basic (in usd per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.81

-0.71

-0.65

-

-0.60

-0.69

-1.93

106.80

-55.92

-75.25

25.54

Diluted (in usd per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.81

-0.71

-0.65

-

-0.60

-0.69

-1.93

111.22

-55.92

-75.25

21.00

Weighted-average number of shares used in computing net loss per share attributable to common stockholders:
Basic and diluted weighted-average number of shares used in computing net loss per share (in shares)

53,868

45,669

43,314

43,260

41,598

36,339

36,272

36,123

35,950

31,549

30,270

29,776

28,808

28,203

28,160

28,089

28,005

-

-

-

-

-

-

-

-

-

-

-

-

Basic (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

23,755

23,584

23,535

-

23,331

19,380

11,092

238

228

209

204

Diluted (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

23,755

23,584

23,535

-

23,331

19,380

11,092

3,042

228

209

635